Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from iex and EODHD
Download Data

Monte Rosa Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Monte Rosa Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 7 6 7 - - - - - - - - - - - - - -
Gross Profit
M 3 -6 -7 - - - - - - - - - - - - - -
Operating Expenses
M 147 137 134 - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 34 32 32 30 28 27 25 23 20 16 13 9 6 4 2 1 0
Research and Development (R&D) Expenses
M 108 109 109 102 94 85 78 72 66 57 49 39 29 24 14 9 4
Other Operating Expenses
M 6 -4 -7 - - - - - - - - - - - - - -
Costs and Expenses
M 134 135 134 - - - - - - - - - - - - - -
Operating Income
M -144 -143 -141 -132 -122 -112 -103 -95 -86 -73 -61 -48 -35 -28 -16 -10 -4
Interest Expense
M 1 -1 3 4 5 4 2 1 0 0 0 0 0 0 0 0 0
Non-operating Income/Expense
M 7 6 6 5 6 4 2 1 0 -1 -9 -9 -9 -8 0 0 0
EBT
M -135 -135 -133 -125 -117 -109 -101 -94 -86 -74 -70 -57 -44 -36 -16 -10 -4
Income Tax Provision
M 0 -2 -4 -5 -6 -4 -3 -3 -1 -1 0 0 0 0 0 0 0
Income after Tax
M -135 -133 -129 -120 -111 -105 -98 -91 -84 -73 -70 -57 -44 -36 -16 -10 -4
Non-Controlling Interest
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Income
M -35 -67 -98 -125 -117 -109 -101 -94 -86 -74 -51 -37 -24 -16 -16 -10 -4
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 54,082,664.75 51,380,486.25 49,371,864.50 48,601,227.00 47,910,338.75 47,222,416.00 46,496,092.50 46,309,970.75 35,910,517.00 34,896,625.25 28,834,110.50 22,771,595.75 26,938,409.00 21,737,807.00 21,737,807.00 21,737,807.00 21,737,807.00
EBITDA
M -139 -140 -139 -129 -120 -110 -101 -93 -84 -72 -60 -46 -34 -27 -16 -10 -4
Depreciation and Amortization
M 7 5 4 3 2 3 3 3 2 2 2 1 1 1 0 0 0
EBIT
M -146 -145 -143 -132 -122 -112 -104 -96 -87 -74 -62 -48 -35 -28 -16 -10 -4
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% -0.06 1.74 3.11 3.94 4.79 3.45 2.87 2.69 1.58 1.58 0.72 -0.71 -0.17 -0.57 -0.70 0.26 -0.07
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit Margin
% 0.31 - - - - - - - - - - - - - - - -
Operating Income Margin
% -1,841.42 - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% -1,741.73 - - - - - - - - - - - - - - - -
EBIT Ratio
% -1,841.42 - - - - - - - - - - - - - - - -
EBT Ratio
% -1,688.45 - - - - - - - - - - - - - - - -

StockViz Staff

September 19, 2024

Any question? Send us an email